Cargando…

The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?

Antipsychotic polypharmacy in psychotic disorders is widespread despite international guidelines favoring monotherapy. Previous evidence indicates the utility of low-dose partial dopamine agonist (PDAs) add-ons to mitigate antipsychotic-induced metabolic adverse effects or hyperprolactinemia. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lippi, Matteo, Fanelli, Giuseppe, Fabbri, Chiara, De Ronchi, Diana, Serretti, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521590/ https://www.ncbi.nlm.nih.gov/pubmed/35815937 http://dx.doi.org/10.1097/YIC.0000000000000417

Ejemplares similares

Clinical specificity profile for novel rapid acting antidepressant drugs
por: Scala, Mauro, et al.
Publicado: (2023)

Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder
por: Olgiati, Paolo, et al.
Publicado: (2022)

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

Super-Kamiokande worth full restoration
por: Mishima, I
Publicado: (2002)

Pharmacogenetics of Antidepressants
por: Crisafulli, Concetta, et al.
Publicado: (2011)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Incomplete Coverage of Candidate Genes: A Poorly Considered Bias
por: Drago, Antonio, et al.
Publicado: (2007)

Pharmacogenetics of antidepressant response: An update
por: Drago, Antonio, et al.
Publicado: (2009)

Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
por: Fanelli, Giuseppe, et al.
Publicado: (2022)

Age or age of onset: which is the best criterion to classify late-life depression?
por: Olgiati, Paolo, et al.
Publicado: (2023)

Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder
por: Olgiati, Paolo, et al.
Publicado: (2023)

How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach
por: Fabbri, Chiara, et al.
Publicado: (2020)

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
por: Fabbri, Chiara, et al.
Publicado: (2020)

Acute psychosis: A neuropsychiatric dilemma
por: Saldanha, Daniel, et al.
Publicado: (2013)

Dilemma of Treating Psychosis Secondary to Stroke
por: Agrawal, Ruchita, et al.
Publicado: (2021)

CRY1 Variations Impacts on the Depressive Relapse Rate in a Sample of Bipolar Patients
por: Drago, Antonio, et al.
Publicado: (2015)

Laparoscopic Partial Nephrectomy: Is It Worth Still Performing the Retroperitoneal Route?
por: Ouzaid, Idir, et al.
Publicado: (2012)

Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis
por: Bojesen, Kirsten Borup, et al.
Publicado: (2023)

“Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic
por: Blum, Kenneth, et al.
Publicado: (2017)

Pharmacogenetics and Depression: A Critical Perspective
por: Corponi, Filippo, et al.
Publicado: (2019)

Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases
por: Serretti, Alessandro, et al.
Publicado: (2007)

Delta Variant: Partially Sensitive To Vaccination, but Still Worth Global Attention
por: Zhang, Meng, et al.
Publicado: (2022)

Managing Bipolar Disease Complicated with Psychosis in Conjunction with Polypharmacy, Parkinson's Disease, and Multiple Comorbidities
por: Irizarry, Ricardo, et al.
Publicado: (2022)

MON-382 An Adrenal Incidentaloma: The Dilemma over Dopamine
por: Yedla, Niharika, et al.
Publicado: (2019)

Is It Worth It?
por: Card, W. I.
Publicado: (1979)

The dilemma of partial nephrectomy and surgical upstaging
por: dos Reis, Rodolfo Borges, et al.
Publicado: (2022)

Genetics of Late-Onset Alzheimer's Disease: Update from the Alzgene Database and Analysis of Shared Pathways
por: Olgiati, Paolo, et al.
Publicado: (2011)

Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report
por: Scala, Mauro, et al.
Publicado: (2023)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis
por: Oehrn, Carina R., et al.
Publicado: (2021)

Dopamine, Psychosis, and Symptom Fluctuation: A Narrative Review
por: Novak, Gabriela, et al.
Publicado: (2022)

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment
por: Fabbri, Chiara, et al.
Publicado: (2020)

Imputed expression of schizophrenia‐associated genes and cognitive measures in patients with schizophrenia
por: Fabbri, Chiara, et al.
Publicado: (2022)

Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank
por: Fabbri, Chiara, et al.
Publicado: (2023)

Multimorbidity and Polypharmacy in Psychosis: Identifying Potentially Significant Drug Interactions in an Old Age Inpatient Psychiatry Setting
por: Tewari, Abhinav, et al.
Publicado: (2023)

It works. And it's worth it
por: Rutherford, Adam
Publicado: (2009)

Worth's Squint
Publicado: (1915)

The Worthing Experiment
Publicado: (1958)

The Worth of Inflammation
Publicado: (1892)

The Worth of Words
Publicado: (1904)

Cannot write session to /tmp/vufind_sessions/sess_79g7bqk1pvitap36peddjlposl